Prevalence and Outcomes of Primary Hyperparathyroidism in Sarcoidosis Patients: A Large-Scale Retrospective Cohort Study

Clicks: 31
ID: 322719
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #262 of 457 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 457 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
PRÉCIS: Among 117,395 U.S. adults with sarcoidosis, primary hyperparathyroidism was markedly underdiagnosed: 75.4% of biochemically defined cases carried no corresponding ICD-10 code, and parathyroidectomy was associated with a 4.2-fold reduction in 3-year mortality. CONTEXT: Hypercalcemia in sarcoidosis is classically attributed to granuloma-mediated calcitriol excess, but primary hyperparathyroidism (PHPT)-the most common cause of ambulatory hypercalcemia-frequently coexists. These two etiologies are mechanistically distinct: sarcoid hypercalcemia is suppressed-PTH and 1,25(OH)2D-driven, while PHPT is autonomous-PTH-driven and surgically curable. Because both can independently sustain hypercalcemia, attribution to sarcoidosis alone risks anchoring bias and delayed identification of PHPT. OBJECTIVE: To determine PHPT prevalence in sarcoidosis, characterize hypercalcemia-evaluation adequacy, and assess parathyroidectomy (PTX) impact on all-cause mortality. DESIGN: Retrospective cohort study. SETTING: TriNetX U.S. Collaborative Network, federated EHR data from >120 million patients. PATIENTS: 117,395 adults with ICD-10 sarcoidosis (D86) and ≥1 serum calcium measurement. INTERVENTIONS: None (observational). MAIN OUTCOME MEASURES: iPTH assessment rate; biochemical and coded PHPT prevalence; PTX utilization and outcomes; all-cause mortality. RESULTS: Hypercalcemia: 31.3% (n=36,790); only 30.5% received iPTH. Biochemical PHPT: 3.0% (n=3,493)-of whom 75.4% (n=2,633) had no ICD-10 code. PTX in coded PHPT: 36.6% (n=315), with 74.6% biochemical cure. Hypercalcemia HR 1.33 (1.29-1.38), coded PHPT HR 1.50 (1.40-1.60), no-PTX HR 4.2 (2.7-6.4); all p<0.001. CONCLUSIONS: PHPT is prevalent, profoundly under-evaluated, and undertreated in sarcoidosis. Routine iPTH measurement and timely surgical referral are essential.
Reference Key
openalex_W7171546312 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag302
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.